Caroline Harstroem, MD
Pain Medicine · Everett, WANPI 1396131975
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (36.0%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Nevro Corp. at 34.7% of the total. 2025 is the largest year on record at $30,542, more than ten times the $543 reported in 2020. Among pain medicine clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 408 payments — averaging $182.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Nevro Corp.$26K
- Nalu Medical, Inc.$21K
- Globus Medical$9K
- Abbott$6K
- Saluda Medical Americas, Inc.$4K
- MML US, Inc.$4K
- plus $5K from 18 others
Across 13 payments — averaging $2817.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Si-bone, Inc.$37K
What the payments were for
- Consulting fees$26,77836%
- Speaking & faculty fees$13,69518%
- Travel & lodging$13,32418%
- Food & beverage$20,48128%
- Entertainment$430%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Nevro Corp. | 126 | $25,800 |
| Nalu Medical, Inc. | 31 | $20,576 |
| Globus Medical | 24 | $8,835 |
| Abbott | 76 | $5,979 |
| Saluda Medical Americas, Inc. | 37 | $4,491 |
| MML US, Inc. | 27 | $3,717 |
| Boston Scientific | 21 | $1,527 |
| Si-bone, Inc. | 15 | $789 |
| Vertos Medical, Inc. | 9 | $574 |
| Foundation Fusion Solutions, LLC | 5 | $518 |
| Spinal Simplicity, LLC | 3 | $388 |
| SPR Therapeutics, Inc | 7 | $368 |
| Relievant Medsystems, Inc. | 5 | $318 |
| Medtronic(2 entities) | 5 | $117 |
| Collegium Pharmaceutical, Inc. | 5 | $82 |
| Biodelivery Sciences International, Inc. | 3 | $48 |
| Axonics, Inc. | 1 | $38 |
| Painteq LLC | 2 | $30 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $24 |
| Fidia Pharma USA Inc. | 1 | $24 |
| Arbor Pharmaceuticals, Inc. | 1 | $22 |
| Biotronik NRO, Inc. | 1 | $19 |
| Kowa Pharmaceuticals America, Inc. | 1 | $19 |
| Biohaven Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Senza$21,612
- Nalu Neurostimulation System$19,956
- Omnia$9,031
- PROCLAIM$3,254
- ReActiv8$3,052
- Evoke SCS$2,739
- Evoke$1,146
- ETERNA$1,106
- Intracept$620
- GENERAL PAIN MANAGEMENT$529
- HA MINUTEMAN G3-R$369
- mild Device Kit$266
- Senza II$236
- SPRINT PNS System$231
- WAVEWRITER ALPHA$147
- Senza Spinal Cord Stimulation System$133
How this compares
$74,321 in reported general payments places this provider in the 95th percentile of 124 pain medicine providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine | 123 | $30,030 |
| BelbucaBuprenorphine Hcl | 16 | $13,609 |
| Xtampza ErOxycodone Myristate | 18 | $9,926 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 244 | $6,970 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 171 | $6,569 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 61 | $6,268 |
| SymproicNaldemedine Tosylate | 12 | $5,460 |
| Oxycodone Hcl | 340 | $5,063 |
| Buprenorphine Hcl | 96 | $4,104 |
| Pregabalin | 79 | $2,577 |
| Tramadol Hcl ErTramadol Hcl | 41 | $2,358 |
| Morphine Sulfate ErMorphine Sulfate | 61 | $1,827 |
| Naloxone Hcl | 20 | $1,346 |
| Tramadol Hcl | 92 | $1,199 |
| Tizanidine Hcl | 58 | $993 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er | $82 | $23,53634 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 124 pain medicine providers in Washington.
Other pain medicine in Everett
- Jennifer LeeKirkland$318K
- Steven StanosSeattle$206K
- Corrie AndersonSeattle$102K
- Gregory TermanSeattle$95K
- Sloane YuVancouver$42K
- Praveen MambalamEdmonds$32K
- Miroslav BackonjaSeattle$22K
- Ross VogelgesangOlympia$21K
- Jon HillyerSilverdale$20K
- Nathan SneddonSpokane Valley$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.